From ASCO: Updates in HER2-positive breast cancers
PUBLISHED: 5:17 PM, WED JUNE 5, 2013
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Hear financial expert and registered nurse Mary Ann Cagle discuss the financial burden of cancer, often a result of expensive treatments, appointments, and diagnostic tests. Learn where to look for possible financial support.